To Detect Neuroendocrine Prostate Cancer Genomic and DNA Methylation Changes
PROSTATE CANCER - ADVANCED 8 General Session, Thu, 3:00 PM-4:25 PM Circulating tumor DNA (ctDNA) to detect neuroendocrine prostate cancer genomic and DNA methylation changes. Himisha Beltran, Alessandro Romanel, Vincenza Conteduca, Nicola Casiraghi, Michael Sigouros, Gian Marco Franceschini, Tarcisio Fedrizzi, sheng-Yu Ku, Alicia Alonso, Juan Miguel Mosquera, Emma Dann, Andrea Sboner, Jenny Xiang, Olivier Elemento, David M. Nanus, Scott T. Tagawa, Matteo Benelli, Francesca Demichelis; Dana-Farber Cancer Institute, Boston, MA; University of Trento, Trento, Italy; Dana Farber Cancer Institute, Boston, MA; Department of Medicine, Division of Medical Oncology, Weill Cornell Medicine, New York City, NY; Weill Cornell Medicine, New York, NY; Department of Pathology & Laboratory Medicine, Englander Institute for Precision Medicine, Weill Cornell Medical College & New York-Presbyterian Hospital, New York, NY; Weill Cornell Medical College, New York, NY; Department of Physiology and Biophysics, Institute for Computational Biomedicine, Englander Institute for Precision Medicine, Weill Cornell Medical College, New York, NY; Sandra and Edward Meyer Cancer Center, New York, NY; Department of Cellular, Computational and Integrative Biology, University of Trento, Trento, Italy Background: Loss of androgen receptor signaling dependence occurs in approximately 20% of treatment resistant prostate cancers, and this may manifest as transformation to castration resistant neuroendocrine prostate cancer (CRPC-NE). The diagnosis of CRPC-NE relies on a metastatic tumor biopsy, which is invasive for patients. Here we study ctDNA as an approach to identify CRPC-NE-associated genomic and epigenomic changes. We also use this as a tool to understand tumor heterogeneity and clonal dynamics that occurs during CRPC-NE progression. Methods: 64 patients with metastatic prostate cancer (10 hormone naive, 35 castration resistant adenocarcinoma (CRPC-Adeno), 17 CRPC-NE) were prospectively enrolled for matched metastatic biopsy and blood collection.
[Show full text]